Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CA6 | P23280 | 5/20 | 0.50 |
| ▸ | CA7 | P43166 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA5A | P35218 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | CA3 | P07451 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10123924 | 0.95 | CYP2C19 (0.54) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL323463 | 0.95 | CYP2C19 (0.58) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL8350386 | 0.93 | CYP2C19 (0.52) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL10123895 | 0.93 | CYP2C19 (0.52) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL24193268 | 0.93 | CYP2C19 (0.52) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL30607521 | 0.93 | CYP2C19 (0.56) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL11871853 | 0.93 | CYP2C19 (0.56) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL22404850 | 0.91 | CYP2C19 (0.50) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL13827089 | 0.89 | CYP2C9 (0.48) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL13827055 | 0.89 | CYP2C19 (0.54) | CYP2C19CYP2C9CA12CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | CYP2C19 653/4885CYP2C9 633/4885CA12 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.